Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases

被引:10
|
作者
Nali, Luiz H. [1 ,2 ]
Olival, Guilherme S. [3 ]
Sousa, Francielle T. G. [1 ]
de Oliveira, Ana Carolina S. [1 ]
Montenegro, Horacio [4 ]
da Silva, Israel T. [5 ]
Dias-Neto, Emamnuel [5 ,6 ]
Naya, Hugo [7 ]
Spangenberg, Lucia [7 ]
Penalva-de-Oliveira, Augusto C. [8 ]
Romano, Camila M. [1 ,9 ]
机构
[1] Univ Sao Paulo, Lab Virol, Inst Medicina Trop Sao Paulo, LIM52 LIMHC, Rua Dr Eneas de Carvalho Aguiar, BR-05403000 Sao Paulo, Brazil
[2] Univ Santo Amaro, Postgraduat Program Hlth Sci, Rua Prof Eneas Siqueira Neto 340, BR-04829300 Sao Paulo, Brazil
[3] Dept Neurol Santa Casa Misericordia Sao Paulo, R Dr Cesario Mota Jr 112, BR-01221020 Sao Paulo, Brazil
[4] ESALQ USP, Dept Zootecnia, BR-13400183 Piracicaba, SP, Brazil
[5] AC Camargo Canc Ctr, Lab Med Genom, BR-01525001 Sao Paulo, Brazil
[6] Univ Sao Paulo, Sao Paulo Med Sch, Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo, Brazil
[7] Unidad Bioinformat Inst Pasteur Montevideo, Mataojo 2020, Montevideo 11400, Uruguay
[8] Inst Infectol Emilio Ribas, Dept Neurol, Ave Doutor Arnaldo 165, BR-01246900 Sao Paulo, Brazil
[9] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP LIM52, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
Multiple Sclerosis; Transcriptome; gene expression; RRMS; SPMS; NERVE GROWTH-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE-EXPRESSION; PEPTIDYLARGININE DEIMINASE-2; INDUCTION; TYPE-1; PAD2; RISK; NATALIZUMAB; CYTOKINES;
D O I
10.1016/j.msard.2020.102243
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis (MS) is an inflammatory autoimmune neurologic disease that causes progressive destruction of myelin sheath and axons. Affecting more than 2 million people worldwide, MS may presents distinct clinical courses. However, information regarding key gene expression and genic pathways related to each clinical form is still limited. Objective: To assess the whole transcriptome of blood leukocytes from patients with remittent-recurrent (RRMS) and secondary-progressive (SPMS) forms to explore the gene expression profile of each form. Methods: Total RNA was obtained and sequenced in Illumina HiSeq platform. Reads were aligned to human genome (GRCh38/hg38), BAM files were mapped and differential expression was obtained with DeSeq2. Up or downregulated pathways were obtained through Ingenuity IPA. Pro-inflammatory cytokines levels were also assessed. Results: The transcriptome was generated for nine patients (6 SPMS and 3 RRMS) and 5 healthy controls. A total of 731 and 435 differentially expressed genes were identified in SPMS and RRMS, respectively. RERE, IRS2, SIPA1L1, TANC2 and PLAGL1 were upregulated in both forms, whereas PAD2 and PAD4 were upregulated in RRMS and downregulated in SPMS. Inflammatory and neuronal repair pathways were upregulated in RRMS, which was also observed in cytokine analysis. Conversely, SPMS patients presented IL-8, IL-1, Neurothrophin and Neuregulin pathways down regulated. Conclusions: Overall, the transcriptome of RRMS and SPMS clearly indicated distinct inflammatory profiles, where RRMS presented marked pro-inflammatory profile but SPMS did not. SPMS individuals also presented a decrease on expression of neuronal repair pathways.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools
    Klinsing, Svenja
    Yalachkov, Yavor
    Foerch, Christian
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (04) : 1100 - 1105
  • [42] Disability progression of active and nonactive primary and secondary progressive multiple sclerosis patients in the US
    Watson, C.
    Sadetsky, N.
    Thirumalai, D.
    Barlev, A.
    Grant, N.
    Jones, E.
    Bogdanovich, S.
    Kresa-Reahl, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 466 - 466
  • [43] A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-lb in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis
    Touchette, DR
    Durgin, TL
    Wanke, LA
    Goodkin, DE
    CLINICAL THERAPEUTICS, 2003, 25 (02) : 611 - 634
  • [44] Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Lundy, Steve K.
    Dowling, Catherine
    Segal, Benjamin Matthew M.
    Fox, David
    Wallstroem, Erik
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 12 - 12
  • [45] Baseline immunological profile in secondary progressive multiple sclerosis patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Lundy, Steve K.
    Segal, Benjamin Matthew M.
    Wallstroem, Erik
    Fox, David A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 13 - 13
  • [46] Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayers, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Lundy, Steven
    Segal, Benjamin
    Wallstrom, Wallstrom
    NEUROLOGY, 2016, 86
  • [47] Expression analysis of apoptotis-related genes in patients with relapsing and progressive forms of multiple sclerosis
    Moreno, M.
    Negrotto, L.
    Moubarak, R.
    Castillo, J.
    Sastre-Garriga, J.
    Comella, J. X.
    Montalban, X.
    Comabella, M.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 147 - 147
  • [48] iNKT cells in secondary Progressive Multiple sclerosis Patients Display Pro-inflammatory Profiles
    De Biasi, Sara
    Simone, Anna Maria
    Nasi, Milena
    Bianchini, Elena
    Ferraro, Diana
    Vitetta, Francesca
    Gibellini, Lara
    Pinti, Marcello
    Del Giovane, Cinzia
    Sola, Patrizia
    Cossarizza, Andrea
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [49] THE EVALUATION OF WORK PRODUCTIVITY IN RELAPSING-REMITTING (RRMS) AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) PATIENTS IN EUROPE
    Pike, J.
    Naoshy, S.
    Watson, C.
    Jones, E.
    VALUE IN HEALTH, 2015, 18 (03) : A289 - A289
  • [50] Development of an objective testbattery for motor and cognitive fatigue in patients with relapsing-remitting and secondary progressive multiple sclerosis
    Hofstadt-van Oy, U.
    Menge, U.
    Weimer, R.
    Burschka, J.
    Oschmann, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 108 - 108